Tiotropium bromide monohydrate and olodaterol hydrochloride (Spiolto® Respimat®) combination inhaler for Chronic Obstructive Pulmonary Disease (COPD)

NHS Devon

Commissioning policy

The routine commissioning of tiotropium bromide monohydrate 2.5 mcg and olodaterol hydrochloride 2.5 mcg (Spiolto® Respimat®) combination inhaler is accepted in Devon for the treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults. The Formulary Interface Group should include this in locally defined treatment recommendations.

Rationale for the decision

Spiolto® Respimat® is a soft mist combination inhaler for COPD containing two active ingredients: tiotropium bromide monohydrate, a long-acting muscarinic antagonist (LAMA), and olodaterol hydrochloride, a long-acting beta-2 agonist (LABA).

The use of LAMA/LABA combination inhalers is established in the management of COPD and is recommended in current NICE guidance and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.

Four randomised controlled trials (RCTs) showed that Spiolto® Respimat® substantially improved lung function, breathlessness, and health related quality of life. Clinically important differences were seen compared with placebo, but not always when compared with individual monotherapy inhalers.

There are currently no head-to-head randomised controlled trials comparing Spiolto® Respimat® with the other LAMA/LABA combination inhalers. A network meta-analysis of RCT efficacy data suggests that there is no clinically important difference between Spiolto® Respimat® and other LAMA/LABA combination inhalers.

Spiolto® Respimat® has the same acquisition cost as other LAMA/LABA combination inhalers (and it is cheaper than the combined cost of individual component inhalers).

Spiolto® Respimat® may be suitable for patients who either require or prefer a soft mist inhaler over a dry powder inhaler, and it would allow patients currently on tiotropium to step-up from an individual monotherapy inhaler without changing their device or LAMA.

Guidance notes on exceptionality

Not applicable.

Date of publication:	Version:
26.09.2017	Policy agreed by Northern, Eastern and Western Devon CCG and South Devon and Torbay CCG Policy adopted by NHS Devon CCG on 01.04.2019 Policy adopted by NHS Devon ICB on 01.07.2022